The Relationship between Serum Vitamin D Level and Attention Deficit Hyperactivity Disorder

How to Cite This Article: Sharif MR, Madani M, Tabatabaei F, Tabatabae Z. The Relationship between Serum Vitamin D Levels and Attention Deficit Hyperactivity Disorder. Iran J Child Neurol. Autumn 2015;9(4): 48-53.

Abstract

Objective

Attention deficit hyperactivity disorder (ADHD) is one of the most prevalent mental health disorders. In recent years, the impacts of various micronutrients on ADHD have been studied. However, vitamin D has received much less attention. This study was aimed at evaluating the association and level of serum vitamin D in children with ADHD.

Materials & Methods

This case-control study was carried out, in 2012, on 6 to 12 yr-old children. Thirty-seven were children with ADHD in the cases group and another 37 healthy children were in the control group. Venous blood sample was drawn from each child to measure the serum level of vitamin D. Other variables were compared as well.

Results

The mean serum vitamin D level of children with ADHD (19.11±10.10 ng/ml) was significantly lower than that of the control group (28.67±13.76 ng/ml) (P<0.001).

Conclusion

Deficiency of vitamin D has been proved in various psychiatric diseases. This study evidenced a significantly low level of serum vitamin D in children with ADHD. This suggests the need for regularly monitoring of serum vitamin D levels and treatment of patients with vitamin D deficiencies.

Keywords: Vitamin D; Children; Psychiatric diseases; ADHD

Introduction

Attention deficit hyperactivity disorder (ADHD) is one of the most prevalent mental health disorders that affect about 5.3–7.1 percent of children and adolescents (1). Attention deficiency, hyperactivity and impulsivity are three main symptoms that help diagnose the disorder before the age of twelve years (1, 2). Besides, other accompanying secondary symptoms such as aggression, social incompetence, conflict with peers and anti-social behavior other clinically important symptoms (2, 3).

So far, drug therapy is the main treatment method. However, there are limitations in drug interventions. For instance, 30 percent of ADHD children do not respond to the drug treatment (4, 5). More effective treatment and strategies are needed to control the disease (6, 7). In recent years, the role of environment (8-10) and more specifically the role of nutrition in the prevention and treatment of the symptoms of the disease have been attracting the attention of researchers (11-13). Diet therapy is a simple
and inexpensive method that can be readily accepted by the parents and adopted by the children. Nutrition therapy, especially the role of supplements and vitamins is very pronounced (11). The role of micronutrients such as iron (14-16), zinc (17, 18) and omega three (19) on the prevention and control of the symptoms have been extensively studied. However, the role of vitamin D has attracted less attention. This condition exists despite the fact that vitamin D deficiency is associated with psychiatric diseases such as autism, schizophrenia, and depression (20-22). This vitamin is not only involved in bone metabolism and serum calcium regulation but also has significant effect on many body organs (23).

Thus, it has been recommended that the level of this vitamin should be checked in pregnant women and their babies (20, 24). Vitamin D deficiency during the fetal period is accounted for some psychological disorders after birth (21). In addition, it has been suggested that vitamin D insufficiency during the fetal and post-natal period has unfavorable effects on the development of the brain structure and functions (20).

This study was designed to examine serum vitamin D level of children diagnosed to have ADHD.

Materials & Methods
This case-control study was carried out in 2012. Healthy children and children diagnosed to have ADHD in the age range of 6 to 12 year-old were eligible to enter the study. Overall, following the completion of consent form, 74 children voluntarily participated in the study. The case group (n=37) included children who had ADHD medical records at a pediatric psychiatric clinic in Isfahan and the control group (n=37) among non ADHD children selected from those who were referred to health centers for checking their weight and height. Their demographic data were collected at the time of referral.

A psychiatrist has ruled out the ADHD and diagnosis was made based on facts from a face-to-face interview with the child and his parents and using the Statistical Manual of Mental Disorders Diagnostic (DSM-IV) criteria (25). After confirming the diagnosis of ADHD, a child would enter the study protocol. A child who suffered from liver, kidney or any endocrine disease or who was on vitamin D supplement was excluded from the study. Besides, a child diagnosed to have mental retardation, autism or seizures was excluded. Parents were explained about the safety and purpose of the study and about confidentiality of every child’s data.

This study was approved by Ethic Committee of Kashan University of Medical Science. After obtaining written informed consent from each participant’s parent, three milliliter (ml) of venous blood was drawn from each child in both the cases and control groups. Standard DIA source kit and ELISA methods were used to measure the level of 25-hydroxi vitamin D. The serum vitamin D level was classified as severely low (< 10 nanograms (ng) per ml), low (10 to 30 ng/ml), normal (30 to 100 ng/ml) or toxic level (> 100 ng/ml) based on the analysis of the blood (26, 27).

Data were analyzed using the statistical packages for social sciences (SPSS) version 16.0 (Chicago, IL, USA). Independent t-test and chi square tests were performed and any association was considered significant at an alpha level of ≤0.05. The parents were informed about if their children found to have below or above normal serum vitamin D levels.

Results
There was no statistically significant difference between the cases and control groups based on age and gender of the study participants. However, there was a statistically significant difference (P < 0.001) in serum vitamin D levels between the cases and the control groups (Table 1).

The serum vitamin D level of 21.6% children in the cases (ADHD) group was normal. The remaining 78.4% children had serum vitamin D level below normal. In the control group, 48.6% of the children had normal serum vitamin D level. None of the children in both groups showed toxic level of vitamin D. Analysis has shown a statistically significant difference (P=0.04) in serum vitamin D levels between the ADHD and the control groups (Table 2).

Furthermore, there was no a statistically significant difference (P=0.3) in serum vitamin D level between boys and girls (21.25±11.52 vs. 21.25±11.52) in the ADHD group of children. Similarly, there was no a statistically significant difference (P=0.9) in the serum vitamin D level of boys and girls (28.71±13.22 vs. 28.63±14.61) in the control group. Besides, there was no
feeding. These studies assume that the nutrient contents of breast milk such as vitamins, minerals, etc. may act as protective agents. However, there is a need for further investigations (35-38). Various studies have examined the effects of micronutrients such as iron, zinc and omega 3 on ADHD, but there is limited evidence suggesting the association between vitamin D deficiency and ADHD. Thus, further studies seem necessary (14-19, 39).

Although little research has implicated the relationship between ADHD and vitamin D, extensive studies have investigated the role of this vitamin in other psychiatric/neurologic disorders (40, 41) including Alzheimer’s disease (42) depression (43, 44), schizophrenia (45) and autism (46).

Since vitamin D is a neurosteroid, lack of this vitamin results in many psychological disorders (20). In addition, vitamin D plays a protective role in brain health, that is, it increases the expression of transpeptidase-glutamyl. This enzyme enhances the formation of glutathione, which is the most important brain antioxidant factor (47). Lack of this vitamin during the fetal life and childhood, in the very early days of life affect the nerve differentiation, axon synapses, brain structure, and function (20).

In the present research, although a considerably high percentage of children in the ADHD had vitamin D deficiency, healthy children in the control was also found to have suffered from vitamin D deficiency. Vitamin D deficiency is a worldwide epidemic. Despite the abundance of sunlight, the prevalence of vitamin D deficiency in countries located around the Persian Gulf region is high. Findings indicated that 70% of very young girls in Iran and 80% in Saudi Arabia suffered from vitamin D deficiency (48). Exposure to sunlight alone is not sufficient to alleviate vitamin D deficiency despite sun light plays a role in maintaining vitamin D level in blood (49).

In conclusion, the low levels of serum vitamin D among the ADHD children suggest the need for regularly monitoring of serum vitamin D levels and treatment of patients with vitamin D deficiencies. In addition, life style and diet should be modified and directed towards eliminating the nutritional deficiencies in the society.

Acknowledgements
The authors would like to appreciate kind assistance and
financial support provided by the Vice Chancellor for Research at Kashan University of Medical Sciences. We thank the parents of our patients for their cooperation and permission to publish this study.

**Conflict of interest:** No conflict of interest

**Authors’ contribution**
Mohammad Reza Sharif: Concept, design and manuscript editing
Mahla Madani: data analysis, manuscript preparation and corresponding author
Fateme Tabatabaei: Data collection and manuscript review
Zakieh Tabatabaei: Data collection, Search for related papers

**Table 1.** Comparison of the relationship of sex, age and Vitamin D levels (ng/ml) with ADHD and Control groups

| Variables | Condition | Gender | Age (yr) | Vitamin D level (ng/ml) |
|-----------|-----------|--------|----------|-------------------------|
|           |           | Boy    | Girl     | Mean        | SD       | Mean | SD  |
| ADHD      | 23 (62%)  | 14 (38.7%) | 9.13 | 2.37 | 19.11 | 10.10 |
| Control   | 18 (48.6%) | 19 (51.4%) | 9.40 | 2.19 | 28.67 | 13.76 |
| Total     | 41 (55.4%) | 33 (44.6%) | 9.27 | 2.27 | 23.89 | 12.92 |
| P         | 0.2       | 0.6    | 0.001    |

**Table 2.** Comparison of serum vitamin D levels of ADHD and control groups

| Variables | Severe deficient n (%) | Deficient n (%) | Normal n (%) |
|-----------|------------------------|-----------------|--------------|
| ADHD      | 11 (29.7)              | 18 (48.6)       | 8 (26.1)     |
| Control   | 6 (16.2)               | 13 (35.1)       | 18 (48.6)    |
| Total     | 17 (23)                | 31 (41.9)       | 26 (35.1)    |
| P         |                       |                 | 0.04         |

**References**
1. Arnold LE, Hodgkins P, Caci H, Kahle J, Young S. Effect of treatment modality on long-term outcomes in attention-deficit/hyperactivity disorder: a systematic review. PLoS One 2015; 25; 10(2):e0116407.
2. Matthews M, Nigg JT, Fair DA. Attention Deficit Hyperactivity Disorder. Curr Top Behav Neurosci 2014; 16: 235–66.
3. Gajria K, Lu M, Sikirica V, Greven P, Zhong Y, Qin P, et al. Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder – a systematic literature review. Neuropsychiatr Dis Treat 2014; 10: 1543-69.
4. Leroux JR. Turgay A. Quinn D. Advances in ADHD treatment. Can J Diagn 2009; 26: 49–52.
5. McGough JJ, Biederman J, Wigal SB, Lopez FA, McCracken JT, Spencer T, et al. Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD. J Am Acad Child Adolesc Psychiatry 2005; 44(6):530-8.
6. Brooke SG, Molina Stephen P, Hinshaw L, Arnold E, James M, et al. Adolescent Substance Use in the...
Multimodal Treatment Study of Attention-Deficit/Hyperactivity Disorder (ADHD) (MTA) as a Function of Childhood ADHD, Random Assignment to Childhood Treatments, and Subsequent Medication. J Am Acad Child Adolesc Psychiatry 2013; 52(3): 250–63.

7. Ghanizadeh A. Predictors of different types of developmental coordination problems in ADHD: the effect of age, gender, ADHD symptom severity and comorbidities. Neuropediatrics 2010; 41(4): 176-81.

8. Halmøy A, Klungsoyr K, Skjærven R, Haavik J. Pre- and perinatal risk factors in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2012; 71(5): 474-81.

9. Budziszewska B, Basta-Kaim A, Kubera M, Lasoń W. [Immunological and endocrinological pattern in ADHD etiopathogenesis]. Przegl Lek 2010; 67(11):1200-4.

10. Banerjee TD, Middleton F, Faraone SV. Environmental risk factors for attention-deficit hyperactivity disorder. Acta Paediatr 2007; 96(9):1269-74.

11. Millichap JG, Yee MM. The diet factor in attention-deficit/hyperactivity disorder. Pediatrics 2012 Feb; 129(2): 330-7.

12. Konikowska K, Regulska-Ilow B, Różańska D. The influence of components of diet on the symptoms of ADHD in children. Roczn Panstw Zakl Hig 2012; 63(2):127-34.

13. Russell G, Ford T, Rosenberg R, Kelly S. The association of attention deficit hyperactivity disorder with socioeconomic disadvantage: alternative explanations and evidence. J Child Psychol Psychiatry 2014; 55(5): 436-45.

14. Gottfried RJ, Gerring JP, Machell K, Yenokyan G, Riddle MA. The iron status of children and youth in a community mental health clinic is lower than that of a national sample. J Child Adolesc Psychopharmacol 2013; 23(2): 91-100

15. Calarge C, Farmer C, DiSilvestro R, Arnold LE. Serum ferritin and amphetamine response in youth with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2010; 20(6): 495-502.

16. Cortese S, Angirman M, Lecendreux M, Konofal E. Iron and attention deficit/hyperactivity disorder: What is the empirical evidence so far? A systematic review of the literature. Expert Rev Neurother 2012; 12(10):1227-40.

17. Arnold LE, Disilvestro RA, Bozzolo D, Bozzolo H, Crowl L, Fernandez S, et al. Zinc for attention-deficit/hyperactivity disorder: placebo-controlled double-blind pilot trial alone and combined with amphetamine. J Child Adolesc Psychopharmacol 2011; 21(1): 1-19.

18. Lepping P, Huber M. Role of zinc in the pathogenesis of attention-deficit hyperactivity disorder: implications for research and treatment. CNS Drugs 2010; 24(9): 721-8.

19. Antalis CJ, Stevens LJ, Campbell M, Padro R, Ericson K, Burgess JR. Omega-3 fatty acid status inattention deficit/hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids 2006; 75(4-5): 299-308.

20. Eyles DW, Burne TH, McGrath JJ. Vitamin D, effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease. Front Neuroendocrinol 2013; 34(1): 47-64.

21. Humble MB, Gustafsson S, Bejerot S. Low serum levels of 25-hydroxyvitamin D (25-OHD) among psychiatric out-patients in Sweden: relations with season, age, ethnic origin and psychiatric diagnosis. J Steroid Biochem Mol Biol 2010; 121(1-2): 467-70.

22. Howland RH. Vitamin D and depression. J Psychosoc Nurs Ment Health Serv 2011; 49(2): 15-8.

23. Cannell JJ, Hollis BW. Use of vitamin D in clinical practice. Altern Med Rev 2008; 13(1): 6-20.

24. Dawodu A, Wagner CL. Mother-child vitamin D deficiency: an international perspective. Arch Dis Child 2007; 92(9): 737-40.

25. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fourth edition (DSM-IV). Washington: The Association 2002.

26. Heaney RP. Health is better at serum 25(OH)D above 30ng/mL. J Steroid Biochem Mol Biol 2013; 136: 224-228.

27. Heaney RP. Defining deficiency of vitamin D. Clin Lab Int 2010; 34: 16-19.

28. Goksugur SB, Tufan AE, Semiz M, Gunes C, Bekdas M, Tosun M, et al. Vitamin D Status in Children with Attention Deficit Hyperactivity Disorder. Pediatr Int 2014; 56(4): 515-9.

29. Kamal M, Bener A, Ehlayel MS. Is high prevalence of vitamin D deficiency a correlate for attention deficit hyperactivity disorder? Atten Defic Hyperact Disord
2014; 6(2): 73-8.
30. Rucklidge JJ, Johnstone J, Gorman B, Boggis A, Frampton CM. Moderators of treatment response in adults with ADHD treated with a vitamin-mineral supplement. Prog Neuropsychopharmacol Biol Psychiatry 2014; 50:163-71.
31. Tolppanen AM, Sayers A, Fraser WD, Lewis G, Zammit S, Lawlor DA. The association of 25-hydroxyvitamin D3 and D2 with behavioural problems in childhood. PLoS One 2012; 7(7):e40097.
32. Arns M, van der Heijden KB, Arnold LE, Kenemans JL. Geographic variation in the prevalence of attention-deficit/hyperactivity disorder: the sunny perspective. Biol Psychiatry 2013; 74(8): 585-90.
33. Rybak YE, McNeely HE, Mackenzie BE, Jain UR, Levitan RD. An open trial of light therapy in adult attention-deficit/hyperactivity disorder. J Clin Psychiatry 2006; 67(10): 1527-35.
34. Hoebert M, van der Heijden KB, van Geijlswijk IM, Smits MG. Long-term follow-up of melatonin treatment in children with ADHD and chronic sleep onset insomnia. J Pineal Res 2009; 47(1):1-7.
35. Millichap JG. Etiologic classification of attention-deficit/ hyperactivity disorder. Pediatrics 2008;121(2):e358-65.
36. Mimouni-Bloch A, Kachevanskaya A, Mimouni FB, Shuper A, Raveh E, Linder N. Breastfeeding may protect from developing attention-deficit/hyperactivity disorder. Breastfeed Med 2013; 8(4):363-7.
37. Shamberger R. Attention-deficit disorder associated with breast-feeding: a brief report. J Am Coll Nutr 2012; 31(4): 239-42.
38. Bener A, Kamal M. Predict attention deficit hyperactivity disorder? Evidence -based medicine. Glob J Health Sci 2013; 6(2):47-57.
39. Gow RV, Hibbelen JR. Omega-3 and treatment implications in Attention Deficit Hyperactivity Disorder (ADHD) and associated behavioral symptoms. Lipid Technology 2014, 26(1): 7–10.
40. McCue RE, Charles RA, Orendain GC, Joseph MD, Abanishe JO. Vitamin d deficiency among psychiatric inpatients. Prim Care Companion CNS Disord 2012; 14(2).
41. Menkes DB, Lancaster K, Grant M, Marsh RW, Dean P, du Toit SA. Vitamin D status of psychiatric inpatients in New Zealand’s Waikato region. BMC Psychiatry 2012; 12:68.
42. Buell JS, Dawson-Hughes B. Vitamin D and neurocognitive dysfunction: preventing “D”ecline. Mol Aspects Med 2008; 29(6):415-22.
43. Hoogendijk WJ, Lips P, Dik MG, Deeg DJ, Beekman AT, Penninx BW. Depression is associated with decreased 25-hydroxyvitamin D and increased parathyroid hormone levels in older adults. Arch Gen Psychiatry 2008; 65(5):508-12.
44. Berk M, Dodd S, Kauer-Sant’anna M, Malhi GS, Bourin M, Kapczinski F, et al. Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr Scand Suppl 2007; (434):41-9.
45. McGrath JJ, Eyles DW, Pedersen CB, Anderson C, Ko P, Burne TH, et al. Neonatal vitamin D status and risk of schizoprenia: A population-based case-control study. Arch Gen Psychiatry 2010; 67(9):889-94.
46. Mostafa GA, Al-Ayadhi LY. Reduced serum concentrations of 25-hydroxy vitamin D in children with autism: relation to autoimmunity. J Neuroinflammation. 2012 Aug 17;9:201.
47. Humble MB. Vitamin D, light and mental health. J Photochem Photobiol B 2010; 101(2): 142-9.
48. Mithal A, Wahl DA, Bonjour JP, Burckhardt P, Dawson-Hughes B, Eisman JA, et al. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int 2009; 20(11): 1807-20.
49. Kliegman RM, Behrman RE, Jenson HB, Stanton BF. Nelson Textbook of Pediatrics. 19th ed. Philadelphia: Elsevier Saunders;2011.